Micron Biomedical, Inc. news

Dr. Mark Prausnitz, co-founder and Chief Scientific Advisor of Micron Biomedical (“Micron”), today presented Micron’s technology for the simple administration of vaccines and therapeutics at a White House panel discussion titled Innovation in Vaccine Delivery chaired by Dr. Francis Collins. This summit outlined a path toward innovative, next-generation COVID-19 vaccines and vaccine delivery technologies, featuring leaders on the cutting-edge of research, dis

– Phase 1/2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of Micron’s Microneedle-Based Measles-Rubella Vaccine –

ATLANTA, July 13, 2021 /PRNewswire/ – Micron Biomedical, Inc. (“Micron” or the “Company”), a leader in dissolving, microneedle-based vaccine and drug delivery, today announced that it has initiated a Phase 1/2 clinical trial of its microneedle-based measles-rubella (“MR”) vaccine

Micron Biomedical, Inc. (Micron) was awarded a new research contract by the Centers for Disease Control and Prevention (CDC) to manufacture IRV microneedle patches for future clinical evaluation. Micron and CDC have been collaborating on the development of the IRV microneedle patch for several years. Preclinical studies of the IRV vaccine, developed by the CDC, delivered using Micron’s dissolving microneedle patch technology show that the IRV microneedle patch is immunogenic and safe in

If some of the many thousands of human volunteers needed to test coronavirus vaccines could have been replaced by digital replicas—one of this year’s Top 10 Emerging Technologies—COVID-19 vaccines might have been developed even faster, saving untold lives. Soon virtual clinical trials could be a reality for testing new vaccines and therapies. Other technologies on the list could reduce greenhouse gas emissions by electrifying air travel and enabling sunlight to dire

Under $6.745 Million Grant from the Bill & Melinda Gates Foundation

ATLANTA, Sept. 1, 2020 /PRNewswire/ — Micron Biomedical, Inc. (Micron) recently received a second tranche of funding ($2.6M) to continue clinical development of its microneedle-based technology for measles and rubella vaccination from the Bill & Melinda Gates Foundation. This work leverages Micron’s technology, which has already been successfully evaluated in clinical studies includi